×
News Home

Exicure (XCUR) Provides Update On The Phase 1b/2 Clinical Trial Of Cavrotolimod

Thursday, August 05, 2021 11:13 AM | Michael Hayne
Exicure (XCUR) Provides Update On The Phase 1b/2 Clinical Trial Of Cavrotolimod

What's Going On With Exicure?

 Exicure (XCUR) today announced interim results from its phase 1b/2 clinical trial of Cavrotolimod (AST-008), which is evaluating cavrotolimod in combination with pembrolizumab (KEYTRUDA) or cemiplimab (LIBTAYO) in patients with metastatic solid tumors. Shares of the company were trading 3.54% lower to $1.36 a share on Thursday. 

What Does This Mean For Exicure?

The ORR in all evaluable MCC patients enrolled in total in the Phase 1b/2 trial was 21% (three of 14) as of the July 1, 2021 data cutoff date. The three patients were comprised of two CRs and one partial response (PR), with a biopsy of individual tumor lesions of the MCC patient assessed as PR by RECIST v1.1 showing no evidence of residual tumor.

“Merkel cell carcinoma is an aggressive skin cancer with a high probability of metastasis. Observing a patient with metastatic MCC who had been previously progressing on pembrolizumab monotherapy and radiation, achieve a complete response, is highly encouraging,” said Dr. Sunandana Chandra, M.D., Assistant Professor at Northwestern University Feinberg School of Medicine and principal investigator in the Phase 1b/2 clinical trial of cavrotolimod.

Cavrotolimod (AST-008) is an SNA that's made up of toll-like receptor 9 agonists designed for immuno-oncology applications. Cavrotolimod is in a Phase 1b/2 clinical trial in patients with advanced solid tumors.

Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology.

Fundamental Score - 83

XCUR has a Fundamental Rank of 83. Find out what this means to you and get the rest of the rankings on XCUR!

Exicure Inc is a clinical-stage biotechnology company that develops a new class of immunomodulatory and gene silencing drugs against validated targets. It uses a spherical nucleic acid technology platform to build a pipeline of products for a range of diseases with unmet medical needs. The company addresses diseases, such as oncology, immunology, and dermatology.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App